DJS Law Group Investigates Corcept for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy CORT?
Source: Newsfilter
- Investigation Launched: DJS Law Group is investigating Corcept Therapeutics for potential violations of securities laws, particularly focusing on whether misleading statements were made or important information was withheld from investors, which could undermine investor confidence.
- FDA Response: On December 31, 2026, Corcept revealed that the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that while the GRACE trial met its primary endpoint, the FDA requires additional evidence of effectiveness, highlighting regulatory hurdles.
- Stock Price Plunge: Following the FDA's announcement, Corcept's shares fell by over 50%, reflecting a pessimistic market sentiment regarding the company's future prospects, potentially leading to significant losses for investors.
- Legal Support: DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through aggressive legal advocacy, demonstrating its commitment to protecting client interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 41.980
Low
50.00
Averages
91.00
High
121.00
Current: 41.980
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 2024 to February 2026, PayPal is accused of overstating its business execution capabilities, leading to investor misconceptions about the company's prospects, which is expected to negatively impact its stock price.
- NuScale Power Risk Disclosure: NuScale is charged with failing to disclose significant risks related to its commercialization strategy during the period from May to November 2025, which could undermine investor confidence in its nuclear projects and affect future financing capabilities.
- Corcept Therapeutics Regulatory Issues: From October 2024 to December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, which may lead to significant obstacles in future drug approvals, impacting company operations.
- Navan IPO Controversy: During its IPO in 2025, Navan is charged with failing to disclose a 39% increase in sales and marketing expenses, which could mislead investors about its financial health and affect its market performance.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Corcept Therapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Corcept securities between October 31, 2024, and December 30, 2025.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the strength of clinical trials supporting their New Drug Application, misrepresenting them as 'powerful support' when the FDA had raised concerns about the adequacy of clinical evidence.
- Misleading Regulatory Outlook: Defendants allegedly misled investors by claiming smooth communication with the FDA and no anticipated obstacles to approval, while failing to disclose significant risks regarding the likelihood of NDA approval, which distorted investors' perceptions of the company's prospects.
- Investor Action Recommendation: Affected investors are encouraged to apply for lead plaintiff status by April 21, 2026, with Bronstein, Gewirtz & Grossman, LLC offering legal representation on a contingency fee basis, ensuring that investors' rights are restored without upfront costs.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025.
- False Statement Allegations: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval.
- Investor Losses: Investors suffered damages when the market learned the truth about Corcept, indicating that the company's public statements were false and materially misleading throughout the class period, leading to a loss of investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages investors who purchased Corcept securities during the class period to contact them before April 21, 2026, to discuss their rights and participate in the lawsuit, offering free legal consultations.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: During the Class Period from 2024 to 2025, Corcept is accused of failing to disclose serious FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, leading to investor misconceptions about the company's prospects.
- Stock Price Crash: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market disappointment in the company's outlook.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, potentially impacting investors' future decision-making based on inaccurate perceptions of the company's operational status.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to secure their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the approval prospects of their lead drug candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter for relacorilant's NDA, indicating that additional evidence was required to assess its effectiveness, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price plummeted from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, reflecting market pessimism regarding the company's future prospects.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 2024 to February 2026, PayPal is accused of overstating its business execution capabilities, leading to investor misconceptions about the company's prospects, which is expected to negatively impact its stock price.
- NuScale Power Risk Disclosure: NuScale is charged with failing to disclose significant risks related to its commercialization strategy during the period from May to November 2025, which could undermine investor confidence in its nuclear projects and affect future financing capabilities.
- Corcept Therapeutics Regulatory Issues: From October 2024 to December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, which may lead to significant obstacles in future drug approvals, impacting company operations.
- Navan IPO Controversy: During its IPO in 2025, Navan is charged with failing to disclose a 39% increase in sales and marketing expenses, which could mislead investors about its financial health and affect its market performance.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Corcept Therapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Corcept securities between October 31, 2024, and December 30, 2025.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the strength of clinical trials supporting their New Drug Application, misrepresenting them as 'powerful support' when the FDA had raised concerns about the adequacy of clinical evidence.
- Misleading Regulatory Outlook: Defendants allegedly misled investors by claiming smooth communication with the FDA and no anticipated obstacles to approval, while failing to disclose significant risks regarding the likelihood of NDA approval, which distorted investors' perceptions of the company's prospects.
- Investor Action Recommendation: Affected investors are encouraged to apply for lead plaintiff status by April 21, 2026, with Bronstein, Gewirtz & Grossman, LLC offering legal representation on a contingency fee basis, ensuring that investors' rights are restored without upfront costs.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025.
- False Statement Allegations: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing that the FDA deemed its clinical data inadequate for approval.
- Investor Losses: Investors suffered damages when the market learned the truth about Corcept, indicating that the company's public statements were false and materially misleading throughout the class period, leading to a loss of investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages investors who purchased Corcept securities during the class period to contact them before April 21, 2026, to discuss their rights and participate in the lawsuit, offering free legal consultations.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: During the Class Period from 2024 to 2025, Corcept is accused of failing to disclose serious FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, leading to investor misconceptions about the company's prospects.
- Stock Price Crash: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market disappointment in the company's outlook.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, potentially impacting investors' future decision-making based on inaccurate perceptions of the company's operational status.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to secure their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the approval prospects of their lead drug candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter for relacorilant's NDA, indicating that additional evidence was required to assess its effectiveness, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price plummeted from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, reflecting market pessimism regarding the company's future prospects.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
